-
Product Insights
Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Drugs In Development, 2023
Global Markets Direct’s, ‘Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Drugs In Development, 2023’, provides an overview of the Clostridioides difficile Infections (Clostridium difficile Associated Disease) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Clostridioides difficile Infections (Clostridium difficile Associated Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete...
-
Product Insights
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Drugs In Development, 2023’, provides an overview of the Methicillin-Resistant Staphylococcus aureus (MRSA) Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Company Profile
Oragenics Inc – Company Profile
Oragenics Inc (Oragenics) focuses on designing of TerraCoV2, immunization product candidate to fight the novel coronavirus. The company is also focused on the development and commercialization of novel antibiotics against infectious diseases, other treatments for oral mucositis and healthcare-associated infections (HAIs). The company's product candidates include OG716, an antibiotic candidate for treating the HAIs; SMaRT Replacement Therapy, a painless treatment to prevent tooth decay; and LPT3-04, a naturally occurring chemical agent that promotes weight loss. It develops product candidates based...
Add to Basket -
Track & Monitor
Innovation in Pharmaceuticals: Alcohol dehydrogenase compositions
Innovation in the pharmaceuticals industry is relentless, making it hard to stay-on top of the dynamically evolving industry landscape and in early identification of profound shifts, posing high risk of being disrupted if detected too late. GlobalData's coherent data-driven approach, using multiple forward-looking alternative datasets, empowers clients by decoding in advance the disruptive innovations in pharmaceuticals industry. Using patents data, GlobalData's proprietary industry innovation s-curve identifies specific innovation areas and their stage of evolution, i.e., whether they are emerging, accelerating...
-
Product Insights
Vancomycin-Resistant Enterococcus Faecium Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The Vancomycin-Resistant Enterococcus Faecium Infections pipeline drugs market research report provides comprehensive information on the therapeutics under development for Vancomycin-Resistant Enterococcus Faecium Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report reviews key players involved in therapeutic development for...
-
Product Insights
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The risk factors of Methicillin-Resistant Staphylococcus Aureus (MRSA) are hemodialysis, weakened immune system, admission to hospitals, and wounds. Symptoms include skin rashes, fatigue, chest pain, fever, and swelling. MRSA can be managed using antibiotics and by maintaining hygienic conditions The Methicillin-Resistant Staphylococcus Aureus pipeline market research report provides comprehensive information on the therapeutics under development for Methicillin-Resistant Staphylococcus Aureus, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The...
-
Product Insights
Clostridioides Difficile Infections (Clostridium Difficile Associated Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Clostridioides difficile Infections – Drugs In Development, 2022, provides an overview of the Clostridioides difficile Infections (Infectious Disease) pipeline landscape. Clostridium difficile infections are caused by Clostridium difficile, often called C. difficile or C. diff, a bacterium that can cause symptoms ranging from diarrhea to life-threatening inflammation of the colon. Symptoms of C. diff infection includes watery diarrhea, with abdominal pain or tenderness, loss of appetite, fever, blood or pus...